A

Performance of Various Lateral Flow SARS-CoV-2 Antigen Self Testing Methods in Healthcare Workers: a Multicenter Study

medRxiv

Abstract

Abstract Introduction Rapid antigen detection tests (RDT) are suitable for large-scale testing for SARS-CoV-2 among the population and recent studies have shown that self-testing with RDT in the general population is feasible and yields acceptable sensitivities with high specificity. We aimed to determine the accuracy of two different RDT’s, with two different sample collection methods for one of the RDT’s among healthcare workers (HCW). Secondary objectives were to determine the accuracy of RDT using a viral load cut-off as proxy of infectiousness and to identify predictors for a false negative RDT. Methods Centers that participated were secondary care hospitals, academic teaching hospitals, and long-term care facilities. All HCW that met inclusion criteria were asked to perform a RDT self-test next to a regular SARS-CoV-2 nucleic acid amplification test (NAAT). Three study groups were created. Study group 1; Veritor(tm) System, Becton Dickinson, Franklin Lakes, USA (BD-RDT) with combined oropharyngeal - mid-turbinate nasal sampling, group 2; BD-RDT with mid-turbinate nasal sampling only and group 3; SD Biosensor SARS-CoV-2 Rapid Antigen Test, Roche, Basel, Switzerland (Roche-RDT) with combined oropharyngeal - mid-turbinate nasal sampling. RDT accuracy was calculated using NAAT as reference standard. For samples processed in the cobas ® 6800/8800 platform (Roche Diagnostics, Basel, Switzerland), established cycle threshold values (Ct-values) could be converted into viral loads. A viral load cut-off of ≥5.2 log10 SARS-CoV-2 E gene copies/ml was used as proxy of infectiousness. Logistic regression analysis was performed to identify predictors for a false negative RDT. Results In total, 7,196 HCW were included. Calculated sensitivities were 61.5% (95%CI 56.6%-66.3%), 50.3% (95%CI 42.8%-57.7%) and 74.2% (95%CI 66.4%-80.9%) for study groups 1, 2 and 3, respectively. After application of a viral load cut-off as a proxy for infectiousness for samples processed in the cobas ® 6800/8800 platform sensitivities increased to 82.2% (95%CI 76.6-86.9%), 61.9% (95%CI 48.8%-73.9%) and 90.2% (95%CI 76.9%-97.3%) for group 1, group 2 and group 3, respectively. Multivariable regression analysis showed that use of Roche-RDT (p <0.01), combined oropharyngeal - mid-turbinate nasal sampling (p <0.05) and the presence of COVID-19 like symptoms at the time of testing (p <0.01) significantly reduced the likeliness of a false-negative RDT result. Conclusion SARS-CoV-2 RDT has proven able to identify infectious individuals, especially when upper respiratory specimen is collected through combined oropharyngeal - mid-turbinate sampling. Reliability of self-testing with RDT among HCW seems to depend on the type of RDT, the sampling method and the presence of COVID-19 like symptoms at the time of testing.

Authors 14

  1. Vivian F. Zwart corresponding
    Affiliation as printed

    Microvida, Laboratory of Medical Microbiology and Immunology, location Amphia, Breda, The Netherlands

    Microvida, Laboratory of Medical Microbiology and Immunology, location Elisabeth-TweeSteden, Tilburg, The Netherlands

  2. Affiliation as printed

    Microvida, Laboratory of Medical Microbiology and Immunology, location Amphia, Breda, The Netherlands

    Microvida, Laboratory of Medical Microbiology and Immunology, location Elisabeth-TweeSteden, Tilburg, The Netherlands

  3. Affiliation as printed

    Microvida, Laboratory of Medical Microbiology and Immunology, location Amphia, Breda, The Netherlands

    Microvida, Laboratory of Medical Microbiology and Immunology, location Elisabeth-TweeSteden, Tilburg, The Netherlands

  4. Leiden University Medical Center

    Affiliation as printed

    Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

  5. Leiden University Medical Center · ZorgSaam

    Affiliation as printed

    Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

    Microvida, Laboratory of Medical Microbiology and Immunology, location Amphia, Breda, The Netherlands

    Microvida, Laboratory of Medical Microbiology and Immunology, location ZorgSaam, Terneuzen, The Netherlands

  6. Bravis Ziekenhuis

    Affiliation as printed

    Microvida, Laboratory of Medical Microbiology and Immunology, location Bravis, Roosendaal, The Netherlands

  7. Affiliation as printed

    Mijzo, Geertruidenberg, The Netherlands

  8. Rijnstate Hospital

    Affiliation as printed

    Laboratory for Medical Microbiology and Immunology, Rijnstate, Arnhem, The Netherlands

  9. Affiliation as printed

    Stichting Prisma, Biezenmortel, The Netherlands

  10. GGZ Oost Brabant

    Affiliation as printed

    GGZ Oost-Brabant, Mental Health Hospital, location Boekel, The Netherlands

  11. Radboud University Medical Center

    Affiliation as printed

    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

  12. Affiliation as printed

    Microvida, Laboratory of Medical Microbiology and Immunology, location Amphia, Breda, The Netherlands

    Microvida, Laboratory of Medical Microbiology and Immunology, location Elisabeth-TweeSteden, Tilburg, The Netherlands

  13. Utrecht University · University Medical Center Utrecht

    Affiliation as printed

    Department of medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

  14. Amphia Ziekenhuis

    Affiliation as printed

    Department of infection control, Amphia, Breda, The Netherlands

    Microvida, Laboratory of Medical Microbiology and Immunology, location Amphia, Breda, The Netherlands

Cited by 8 stored of 9

8 results

No patents citing this paper on Lens.org (checked 2026-10-11).

References 22